Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Long-Term Investments (2016 - 2025)

Sanofi's Long-Term Investments history spans 9 years, with the latest figure at $337.7 million for Q4 2024.

  • For Q4 2024, Long-Term Investments fell 25.98% year-over-year to $337.7 million; the TTM value through Dec 2024 reached $337.7 million, down 25.98%, while the annual FY2024 figure was $342.0 million, 25.43% down from the prior year.
  • Long-Term Investments for Q4 2024 was $337.7 million at Sanofi, down from $456.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $690.7 million in Q4 2022 and bottomed at $239.7 million in Q4 2020.
  • The 5-year median for Long-Term Investments is $337.7 million (2024), against an average of $402.0 million.
  • The largest annual shift saw Long-Term Investments crashed 93.97% in 2020 before it surged 141.51% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $239.7 million in 2020, then rose by 19.34% to $286.0 million in 2021, then soared by 141.51% to $690.7 million in 2022, then plummeted by 33.95% to $456.2 million in 2023, then decreased by 25.98% to $337.7 million in 2024.
  • Per Business Quant, the three most recent readings for SNY's Long-Term Investments are $337.7 million (Q4 2024), $456.2 million (Q4 2023), and $690.7 million (Q4 2022).